# Elicio Therapeutics, Inc. (ELTX) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ELTX
## Company Profile
- Ticker: ELTX
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Immunotherapy, Oncology
## Stock Data
- Close: 3.06 USD
- Market cap: 219299070.69 USD
- Last updated: 2026-08-12
## Business Overview
### Lymph-Node-Targeted Immunotherapies
Elicio Therapeutics develops immunotherapies designed to traffic directly to lymph nodes, where immune responses are coordinated. Its amphiphile technology links therapeutic payloads to albumin for delivery into lymphatic tissue.
### ELI-002 7P
ELI-002 7P is an off-the-shelf therapeutic cancer vaccine targeting seven common KRAS mutations. It is intended to generate mutation-specific T-cell responses in patients with minimal residual disease after surgery.
### Pancreatic Cancer Development
The randomized Phase 2 AMPLIFY-7P study is evaluating ELI-002 7P in patients with resected, KRAS-mutated pancreatic ductal adenocarcinoma, using disease-free survival as its primary endpoint.
## Why The Stock Is Moving

The latest monitored company update is “Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Initiation of a Phase 1 study combining ELI-002 7P with a RAS inhibitor, with or without an anti-PD-1 therapy, in the fourth quarter of 2026.

## Recent News
- 2026-08-13 20:01 EST — [Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-122253de) — Source: Elicio Therapeutics, Inc.
- 2026-08-10 12:00 EST — [Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-activation-of-the-investigator-initiated-phase-1-s-671df539) — Source: Elicio Therapeutics, Inc.
- 2026-07-06 20:05 EST — [Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-closing-of-15-million-registered-direct-offering-a94b4898) — Source: Elicio Therapeutics, Inc.
- 2026-07-02 04:25 EST — [Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-announces-pricing-of-15-million-registered-direct-offering-c7de05c2) — Source: Elicio Therapeutics, Inc.
- 2026-06-29 12:00 EST — [Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/ELTX/elicio-therapeutics-added-to-russell-2000-and-russell-3000-indexes-6dfc9229) — Source: Elicio Therapeutics, Inc.